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I n  spite of great advances in the antimicrobial chemo- 
therapy era, staphylococci are still the most important 
nosocomial pathogens in many countries. The 
methicihn-resistant strains are often resistant not only 
to p-lactam agents but also to chloramphenicol, 
clindamycin, tetracyclines and aminoglycosides. Vanco- 
mycin and teicoplanin are the drugs of choice for the 
treatment of methicillin-resistant Staphylococcus aureus 
(MRSA) infections. Since the relationship between 
plasma levels of teicoplanin and clinical outcome is not 
well established, vancomycin remains the preferred 
agent. 
Various in vitro antibiotic combinations have been 
tested in attempis to find a better treatment regimen for 
staphylococcal infections [1-4]. Because vancomycin is 
the drug generally available for multiresistant staphylo- 
coccal species, the synergistic activities of vancomycin 
with rifampin, amikacin, ciprofloxacin or imipenem 
were tested. 
Five MRSA and five methicillin-sensitive Staphylo- 
coccus aureus (MSSA) strains isolated from blood, pus and 
catheters of patients hospitalized in different intensive 
care units of the same hospital were used in the 
study, and S. aureus ATCC 29213 was used as the 
control strain. The antibiotics were kindly provided 
by the manufacturers: vancomycin (Lilly, USA), 
amikacin (EczacibaSi, Turkey), rifampin (Sifar, Turkey), 
ciprofloxacin (Bayer, Turkey) and imipenem (MSD, 
USA). Methicillin-resistant strains were identified by 
the disk diffusion method with a 1-pg oxacillin disk. 
The minimum inhibitory concentrations (MICs) were 
determined by the broth microdilution method as 
described by the NCCLS [5]. According to MIC values 
of the antibiotics, checkerboard microdilution panels 
were prepared and fractional inhibitory concentrations 
(FICs) of vancomycin-rifampin, vancomycin-amikacin, 
vancomycin-ciprofloxacin and vancomycin-imipenem 
were determined as described elsewhere [6].  Fractional 
inhibitory concentration indices (FICIs) were deter- 
mined for each combination. FICIs0.5 was defined as 
synergy, 0.5<FIC114 as indifference and FICI>4 as 
antagonism [6]. 
The MIC ranges of the antibiotics tested are given 
in Table 1. The mean FICls of the antibiotic com- 
binations are given in Table 2. Vancomycin-amikacin 
was synergistic for all MSSA strains and one MRSA 
strain. Vancomycin-rifampin was indifferent against the 
S. aureus strains tested, either methicilhn sensitive or 
Table 1 MIC ranges of antibiotics tested against 10 
S. aureus isolates 
MSSA (n= 5 )  MRSA (n=5) 
Antibiotics MIC range (mg/L) MIC range (mg/L) 
Vancornycin 0.5-1 0.5-1 
Amikacin 1-2 0.2s to >64 
Rifampin 0.002-0.009 0.009 to >0.6 
Ciprofloxacin 0.03-0.25 0.12 to >2 
Imipeneni 0.12 0.12-8 
MIC, minimum inhibitory concentration; MSSA: methicillin- 
sensitive Staphylococcus aureus; MRSA: methicillin-resistant 
Staphylococcus aurws. 
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Table 2 Mean FIC indices of antibiotic combinations 
against 10 S. aureus isolates deternlined by checkerboard 
microtitration 
V+A V + R  V + C  V+I 
MSSA (strain no.) 
1 0.456 
7 0.398 
3 0.496 
4 0.435 
7 0.382 
MKSA (strain no  ) 
1 0.661 
2 0.499 
3 0.819 
4 1 108 
> 0.983 
1.140 
0.861 
1.228 
1.250 
0.603 
0.980 
1.045 
1.017 
1.233 
1.191 
0.374 
0.437 
0.500 
0.863 
0.745 
1.920 
1.851 
1.150 
1.124 
1.150 
1.037 
1.127 
1.087 
1.108 
1116 
0.480 
0.482 
0.434 
0.498 
0.472 
V, vanconiycin; A, amikacin; R, rifanipin; C, ciprofloxacin; 
I. iiiiipeneni. 
methicillin resistant. All MRSA strains except one were 
resistant to ciprofloxacin and the final effect with the 
vancomycin combination was indifferent, whereas the 
same combination showed synergistic activity against 
most MSSA strains. Vancomycin-imipenem had in 
vitro synergistic activity against all MRSA strains. This 
combination was indifferent for MSSA strains. No 
antagonism was detected among the antibiotics tested. 
MRSA strains have become a major problem in 
hospitalized patients. Most of the MRSA strains are also 
resistant to many other antibiotics, including fluoro- 
quinolones and imipenem. Various combinations of 
antibiotics have been tested for the treatment of 
staphylococcal infections; imipenem and other 
p-lactam antibiotics, glycopeptides and imipeneni or 
nieropenem, vanconiycin and rifampin, rifampin and 
p-lactams, and vancomycin and ciprofloxacin, are some 
of the combinations tested [1,7-111. 
In our study, vancomycin showed synergistic 
activity with ainikacin against the MSSA strains, and 
vancomycin-ciprofloxacin was synergistic against most 
of the MSSA strains. I n  the case of MRSA. the only 
combination having synergistic activity was vanco- 
niycin-iniipeneni. The MIC of vancomycin- 
imipenem was 16-32-fold lower than the MIC of 
inlipenem alone. This synergistic activity could not be 
detected in MSSA strains with the same combination. 
However, since a small number of strains was used in 
the study, additional in vitro and in vivo tests are needed 
to evaluate how representative our findings are. More- 
over, our MRSA strains may be heterogeneously 
resistant to imipenem and the results might be 
somewhat different with homogeneously resistant 
strains. Vancomycin is usually combined with rifampin 
in the treatment of staphylococcal endocarditis or 
osteomyelitis. Our in vitro test results did not show any 
synergistic activity with these antibiotics. The in vitro 
and in vivo data concerning the efficacy of 
vancomycin-rifampin against S. aureus strains have 
been conflicting. Indifferent or even antagonistic inter- 
actions were reported with the checkerboard tech- 
nique, whereas synergistic activity has been shown by 
time kill curve or in vivo models [12-141. In com- 
bination studies, imipeneni and meropeneni were 
reported to have synergistic activity with glycopeptide 
antibiotics against staphylococcal isolates [9,10,15]. We 
have also detected synergy with vancomycin-inlipenem 
against some staphylococcal isolates. However, in vitro 
synergism of vancomycin-imipenem warrants further 
evaluation to determine whether this combination 
could be a possible treatment modality. In vitro 
methods do not always take account of the antibiotic 
concentration changes over time during combination 
therapy [ 161. 
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We have previously established that there is a high 
streptococcal carriage rate among schoolchildren in Al 
Ain, United Arab Emirates (UAE) [l], with the mean 
carriage rate among children examined being 35.4%. 
Further work has demonstrated that the M and T types 
identified from these children were similar to those 
found in the USA and Europe and that the serotype M 
type 1 was prevalent, indicating the potential for serious 
disease in the community [2]. Indeed, post-strepto- 
coccal acute nephritis and acute rheumatic fever are 
well recognized as important local diseases. We were 
interested to learn what the natural history was of those 
in whom we detected streptococci and in those in 
whom we did not. No prophylaxis had occurred 
following our initial studies, and nor was there active 
treatment of those in whom group A streptococci were 
detected. 
This paper reports the findings in the cohort of 
children examined previously for streptococcal carriage 
and compares the findings at a 1-year follow-up exam- 
ination. 
We proposed to re-examine the same cohort of 
schoolchildren that was studied exactly 1 year pre- 
viously. Four schools were revisited and the children 
identified and retested in an identical manner to that 
described previously [l]. Two swabs were obtained 
from the pharynx of each child, one swab being used 
for culture and the other for antigen detection. Direct 
inoculation on sheep blood agar occurred as described 
previously and the Test Pack Strep A immunoassay was 
carried out (Abbott). The children were now aged 
between 6 and 8 years, and the examinations were 
performed in the 'winter' period of 1995-96, corres- 
ponding to the seasonal and calendar months of the 
prior study. As in the previous study, informed consent 
and ethical committee permission was obtained for the 
follow-up aspects. 
From the original study of the 254 children, 146 
children were antigen positive (57%) and 62 culture 
positive (24.4%) for group A P-hemolytic streptococci 
(GAS). At the 1-year follow-up, 110 children were 
antigen positive (43%) and 34 were culture positive 
(13%). However, of the 62 who were originally culture 
positive, only 16 were stlll culture positive (26%), and 
of the 143 who were originally antigen positive, 88 
(61.5%) were still positive. Table 1 outlines the distribu- 
